


sn-Glycero-3-phosphocholine

Cat. No.:	HY-17552
CAS No.:	28319-77-9
Molecular Formula:	C ₈ H ₂₀ NO ₆ P
Molecular Weight:	257.22
Target:	Cholinesterase (ChE); Endogenous Metabolite
Pathway:	Neuronal Signaling; Metabolic Enzyme/Protease
Storage:	4°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (388.77 mM; Need ultrasonic)			
	DMSO : 1.43 mg/mL (5.56 mM; ultrasonic and warming and heat to 60°C)			
		Mass		
	Solvent	Concentration	1 mg	5 mg
	Preparing Stock Solutions		10 mg	
In Vivo	1 mM	3.8877 mL	19.4386 mL	38.8772 mL
	5 mM	0.7775 mL	3.8877 mL	7.7754 mL
	10 mM	0.3888 mL	1.9439 mL	3.8877 mL
	Please refer to the solubility information to select the appropriate solvent.			
In Vivo	1. Add each solvent one by one: PBS Solubility: 150 mg/mL (583.16 mM); Clear solution; Need ultrasonic			
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.09 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.09 mM); Clear solution			
	4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.09 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia ^{[1][2]} .
-------------	--

IC ₅₀ & Target	Human Endogenous Metabolite	
In Vivo	<p>sn-Glycero-3-phosphocholine (Choline Alfoscerate) (250 mg/kg; i.m.; daily for 3 weeks) after seizure can improve seizure-induced cognitive impairment^[2].</p> <p>?sn-Glycero-3-phosphocholine (Choline Alfoscerate) increases the release of acetylcholine in rat hippocampus, facilitates learning and memory in experimental animals, improves brain transduction mechanisms and decreases age-dependent structural changes occurring in rat brain areas involved in learning and memory^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Sprague-Dawley male rats ^[2]
	Dosage:	250 mg/kg
	Administration:	Intramuscular injection; starting at 3 weeks after seizure and continuing daily for 3 weeks
	Result:	Improve seizure-induced cognitive impairment.

CUSTOMER VALIDATION

- J Phys Chem B. 2022 Apr 7;126(13):2466-2475.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Traini E, et al. Choline alphoscerate (alpha-glycerol-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9.

[2]. Lee SH, et al. Late treatment with choline alfoscerate (l-alpha glycerolphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Res. 2017 Jan 1;1654(Pt A):66-76.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA